Filtered By:
Education: Academia
Procedure: Angioplasty

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 243 results found since Jan 2013.

Gender related differences in antiplatelet treatment patterns and outcome: insights from the GreekAntiPlatElet(GRAPE) Registry
ConclusionsIn a contemporary ‘real life’ cohort of ACS patients treated with PCI and focusing on antiplatelet treatment one‐year ischemic outcome does not differ by gender, while women do present more frequently not actionable bleeding events.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2017 Category: Cardiology Authors: I. Xanthopoulou, P. Davlouros, S. Deftereos, M. Hamilos, G. Sitafidis, I. Kanakakis, M. Vavouranakis, J. Goudevenos, J. Lekakis, D. Alexopoulos Tags: Original Research Article Source Type: research

Association of Measured Platelet Reactivity with Changes in P2Y12 Receptor Inhibitor Therapy and Outcomes Following Myocardial Infarction: Insights into Routine Clinical Practice from the TRANSLATE-ACS Study
Conclusions Only one-third of PCI-treated MI patients with high on-clopidogrel platelet reactivity were switched to a more potent P2Y12 receptor inhibitor. Intensification of antiplatelet therapy was associated with lower risk of ischemic events at 1year among HPR patients.
Source: American Heart Journal - February 10, 2017 Category: Cardiology Source Type: research

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI. PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial
Conclusion: The efficacy and safety of CB administered for 12 months for the secondary prevention of atherothrombotic events are similar to that of CHS. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE trial; ClinicalTrials.gov Identifier:NCT02126982).
Source: Journal of Cardiovascular Pharmacology and Therapeutics - October 4, 2016 Category: Cardiology Authors: Ntalas, I. V., Kalantzi, K. I., Tsoumani, M. E., Bourdakis, A., Charmpas, C., Christogiannis, Z., Dimoulis, N., Draganigos, A., Efthimiadis, I., Giannakoulas, G., Giatrakos, I., Giogiakas, V., Goumas, G., Hatziathanasiou, G., Kazakos, E., Kipouridis, N., Tags: Clinical Study Source Type: research

Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
CONCLUSION: This head-to-head comparison of prasugrel and ticagrelor does not support the hypothesis that one is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with primary PCI strategy. The observed rates of major outcomes were similar, although with broad confidence intervals around the estimates. These interesting observations need to be confirmed in a larger trial. CLINICAL TRIAL REGISTRATION: URL: http://www.ClinicalTrials.gov. Unique identifier: NCT02808767. PMID: 27576777 [PubMed - as supplied by publisher]
Source: Circulation - August 29, 2016 Category: Cardiology Authors: Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, Dusek J, Knot J, Jarkovsky J, Kala P, Rokyta R, Tousek F, Kramarikova P, Majtan B, Simek S, Branny M, Mrozek J, Cervinka P, Ostransky J, Widimsky P Tags: Circulation Source Type: research

Taking Risk: Early Results From Teaching Hospitals’ Participation in the Center for Medicare and Medicaid Innovation Bundled Payments for Care Improvement Initiative
The authors describe observations from the 27 teaching hospitals constituting the Association of American Medical Colleges (AAMC) cohort in the Center for Medicare and Medicaid Innovation (CMMI) Bundled Payments for Care Improvement (BPCI) initiative. CMMI introduced BPCI in August 2011 and selected the first set of participants in January 2013. BPCI participants enter into Medicare payment arrangements for episodes of care for which they take financial risk. The first round of participants entered risk agreements on October 1, 2013 and January 1, 2014. In April 2014, CMMI selected additional participants who started takin...
Source: Academic Medicine - June 30, 2016 Category: Universities & Medical Training Tags: Articles Source Type: research

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy Coronary Interventions
Conclusions— ST reporting by an ACL, a CEC, and LIs is discordant. The assessment of ST is more often detected by direct review of angiograms by an ACL. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00527943.
Source: Circulation: Cardiovascular Interventions - May 8, 2016 Category: Cardiology Authors: Popma, C. J., Sheng, S., Korjian, S., Daaboul, Y., Chi, G., Tricoci, P., Huang, Z., Moliterno, D. J., White, H. D., Van de Werf, F., Harrington, R. A., Wallentin, L., Held, C., Armstrong, P. W., Aylward, P. E., Strony, J., Mahaffey, K. W., Gibson, C. M. Tags: Angiography, Imaging, Percutaneous Coronary Intervention Coronary Interventions Source Type: research

Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention
In conclusion, in our population, F2R IVS-14 PAR1 variability does not affect risk of MACE or bleeding following PCI.
Source: Journal of Thrombosis and Thrombolysis - March 30, 2016 Category: Hematology Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One-year outcomes from the GReek AntiPlatelet Registry (GRAPE).
CONCLUSIONS: In real-word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events. This article is protected by copyright. All rights reserved. PMID: 26990959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 16, 2016 Category: Hematology Authors: Alexopoulos D, Xanthopoulou I, Deftereos S, Hamilos M, Sitafidis G, Kanakakis I, Pentara I, Vavouranakis M, Davlouros P, Hahalis G, Goudevenos J Tags: J Thromb Haemost Source Type: research

Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel.
CONCLUSIONS: In this small, retrospective analysis, the results of loading patients with prasugrel for PCI and switching them to clopidogrel without a loading dose appear to be encouraging. PMID: 26378415 [PubMed - in process]
Source: The Journal of Invasive Cardiology - March 11, 2016 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One‐year outcomes from the GReek AntiPlatelet Registry (GRAPE)
ConclusionsIn real‐word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 1, 2016 Category: Hematology Authors: D. Alexopoulos, I. Xanthopoulou, S. Deftereos, M. Hamilos, G. Sitafidis, I. Kanakakis, I. Pentara, M. Vavouranakis, P. Davlouros, G. Hahalis, J. Goudevenos Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications
ConclusionsThe risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel. However, caution with use of bridging anticoagulation should be taken when using ticagrelor.
Source: Clinical Cardiology - January 8, 2016 Category: Cardiology Authors: Angel Fu, Kuljit Singh, Joseph Abunassar, Nikita Malhotra, Michel Le May, Marino Labinaz, Christopher Glover, Jean‐Francois Marquis, Michael Froeschl, Alexander Dick, Benjamin Hibbert, Aun‐Yeong Chong, Derek Y. F. So, Tags: Clinical Investigations Source Type: research

Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population.
CONCLUSION: Our study shows that use of the Supraflex SES in single and multivessel coronary artery disease produces good clinical outcomes during 12 months of follow-up with a low rate of revascularization, despite complex lesion morphology. PMID: 26585397 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 21, 2015 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry
Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI star...
Source: American Heart Journal - September 21, 2015 Category: Cardiology Source Type: research

Harmonizing Optimal Strategy for Treatment of coronary artery diseases – comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial
DiscussionThe HOST-REDUCE-POLYTECH-ACS RCT is the first study exploring the optimal maintenance dose of prasugrel beyond 1 month after PCI for ACS in Asian all-comers. In addition, this is the largest study dedicated only to ACS patients to evaluate the polymer issue in the situation of ACS by directly comparing biostable-polymer PtCr-EES versus BP-BES.Trial registrationClinicalTrials.gov (ID: NCT02193971, 13 July 2014).
Source: Trials - September 15, 2015 Category: Journals (General) Authors: Joo LeeJi-Hyun JungKyung ParkEun-Seok ShinSeok OhJang-Whan BaeJay RhewNamho LeeDong-Bin KimUng KimJung-Kyu HanSang LeeHan-Mo YangHyun-Jae KangBon-Kwon KooSanghyun KimYun ChoWon-Yong ShinYoung-Hyo LimSeung-Woon RhaSeok-Yeon KimSung LeeYoung-Dae KimIn-Ho Ch Source Type: research